Evidence map›Paper›PMID 31159214›Full record

ArticleJournal of clinical medicine2019

Estimating the Level of Carbamoylated Plasma Non-High-Density Lipoproteins Using Infrared Spectroscopy.

Sigurd E Delanghe, Sander De Bruyne, Linde De Baene, Wim Van Biesen, Marijn M Speeckaert, Joris R Delanghe

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sigurd E DelangheDepartment of Nephrology, Ghent University Hospital, 9000 Ghent, Belgium. Sigurd.Delanghe@ugent.be.
Sander De BruyneDepartment of Clinical Chemistry, Ghent University Hospital, 9000 Ghent, Belgium. Sander.Debruyne@uzgent.be.ORCID 0000-0002-9041-4404
Linde De BaeneDepartment of Clinical Chemistry, Ghent University Hospital, 9000 Ghent, Belgium. Linde.Debaene@ugent.be.
Wim Van BiesenDepartment of Nephrology, Ghent University Hospital, 9000 Ghent, Belgium. Wim.Vanbiesen@ugent.be.
Marijn M SpeeckaertDepartment of Nephrology, Ghent University Hospital, 9000 Ghent, Belgium. Marijn.Speeckaert@ugent.be.ORCID 0000-0001-9183-4390
Joris R DelangheDepartment of Clinical Chemistry, Ghent University Hospital, 9000 Ghent, Belgium. Joris.Delanghe@ugent.be.ORCID 0000-0002-5702-6792
Ghent University Hospital · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe increased cardiovascular morbidity and mortality observed in chronic kidney disease (CKD) patients can be partly explained by the presence of carbamoylated lipoproteins. Lipid profiles can be determined with infrared spectroscopy. In this paper, the effects of carbamoylation on spectral changes of non-high-density lipoproteins (non-HDL) were studied.

methodsIn the present study, fasting serum samples were obtained from 84 CKD patients (CKD stage 3-5:

resultsCarbamoylation resulted in a small increase of the amide I band (1714-1589 cm

conclusionsATR-FTIR spectroscopy can be considered as a novel method to detect non-HDL carbamoylation.

Indexed as

carbamoylationchronic kidney diseaseinfrared spectroscopylipoproteins

Identifiers

PMID31159214
PMCPMC6616436
OpenAlexW2947952778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.